Panasas Cuts Data Access Time in Half and Extends the Capabilities of the Industry’s Only Plug-and-Play Parallel File System
Panasas®, the leader in performance scale-out network-attached storage (NAS), today introduced the next generation of its ActiveStor® scale-out NAS solution, capable of scaling capacity to 57PB and delivering 360GB/s of bandwidth. This flexible system doubles metadata performance to cut data access time in half, scales performance and capacity independently, and seamlessly adapts to new technology advancements. The new ActiveStor Director 100 (ASD-100) control-plane engine and the new ActiveStor Hybrid 100 (ASH-100) configurable plug-and-play storage device offer users the flexibility to design storage systems that meet their exact specifications and workflow requirements, now and in the future.
This press release features multimedia. View the full release here: http://www.businesswire.com/news/home/20171108005499/en/
ActiveStor Director 100 (Photo: Business Wire)
“Our research shows that the commercial sector has emerged as the primary area of growth in the high-performance-computing storage market,” said Addison Snell, chief executive officer at Intersect360 Research. “These commercial high-performance segments are often looking for both performance and reliability to achieve efficient performance at scale. Meanwhile, they also need the flexibility to adapt their storage to emerging use cases such as deep learning. The new Panasas ActiveStor solution is aimed directly at these market dynamics.”
The new ActiveStor solution accelerates time to results for traditional and commercial high-performance-computing (HPC) use cases such as manufacturing, life sciences, energy, government, education and research environments, in addition to applications in media and entertainment. It uses the ASD-100, the ASH-100, an updated PanFS® 7.0 parallel file system, and enhancements to the DirectFlow® parallel data-access protocol to deliver these advantages:
Performance – Users can scale metadata performance, data bandwidth, and data capacity independently for faster time to results.
Flexibility – The ability to mix and match HDD and SSD configurations under a single global namespace enables users to best match the system performance to their workload requirements.
Productivity – The new ActiveStor solution doubles productivity by cutting data access time in half, regardless of the number of users.
Investment Protection – The solution is backward and forward compatible with the ActiveStor product portfolio.
“The release of our new ActiveStor solutions reflects our commitment to delivering products that keep pace with new, demanding high-performance applications and workloads,” said Faye Pairman, chief executive officer at Panasas. “These modern ActiveStor solutions deliver a new level of flexibility that enables performance and capacity to scale independently for all data types and file sizes, along with the reliability and manageability that our customers have come to depend on.”
For the first time, Panasas is offering a disaggregated Director Blade (ASD-100), the brain of the Panasas storage system, to provide the ultimate in flexibility. Customers can now add any number of ASD-100s to drive exactly the level of metadata performance they need. With double the raw CPU power and RAM capacity of previous Director Blades, the ASD-100 delivers double the metadata performance on metadata intensive workloads. Based on industry-standard hardware, the ASD-100 manages metadata and the global namespace; it also acts as a gateway for standard data-access protocols such as NFS and SMB. The ASD-100 uses non-volatile dual in-line memory modules (NVDIMMs) to store metadata transaction logs, and Panasas is contributing its NVDIMM driver to the FreeBSD community.
The ASH-100 is the first hardware platform to offer the highest capacity HDD (12TB) and SSD (1.9TB) in a parallel hybrid storage system. A broad range of HDD and SSD capacities can be paired as needed to meet specific workflow requirements. The ASH-100 can be configured with ASD-100s or can be delivered with integrated traditional ActiveStor Director Blades (DBs), depending on customer requirements.
The latest version of the industry’s only plug-and-play parallel file system features an updated FreeBSD operating foundation and a dynamic GUI that supports asynchronous “push” notification of system changes without user interaction.
The updated DirectFlow parallel data access protocol offers a 15 percent improvement in throughput due to enhancements to memory allocation and readahead. All ActiveStor models will benefit from this performance increase after upgrading to the new release of PanFS.
Product Demonstration at SC17
Panasas will demonstrate the new ActiveStor solution in booth #671 at this year’s SC (SuperComputing) conference in Denver, Colorado, being held November 12-17, 2017.
The ASH-100 is shipping now.
The ASD-100 and PanFS 7.0 will be available in Q1 2018.
For more information about the new Panasas ActiveStor solution, including technical specifications, visit www.panasas.com.
Panasas is the performance scale-out NAS leader for unstructured data, driving industry and research innovation by accelerating workflows and simplifying data management. Panasas ActiveStor appliances leverage the patented PanFS storage operating system and DirectFlow protocol to deliver performance and reliability at scale from an appliance that is as easy to manage as it is fast to deploy. Panasas storage is optimized for the most demanding workloads in life sciences, manufacturing, media and entertainment, energy, government as well as education environments, and has been deployed in more than 50 countries worldwide. For more information, visit www.panasas.com.
©2017 Panasas, Inc. Panasas, the Panasas logo, ActiveStor, PanFS, and DirectFlow are registered trademarks or trademarks of Panasas, Inc. Other trademarks are the property of their respective holders.
Rick Popko, 415-800-5381
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Tilaa tiedotteet sähköpostiisi
Haluatko tietää asioista ensimmäisten joukossa? Kun tilaat mediatiedotteemme, saat ne sähköpostiisi välittömästi julkaisuhetkellä. Tilauksen voit halutessasi perua milloin tahansa.
Lue lisää julkaisijalta Business Wire
Incyte Announces Positive Interim Data from Phase 2 Trial of Pemigatinib, Its Selective FGFR Inhibitor, in Patients with Cholangiocarcinoma21.10.2018 13:45 | Tiedote
Incyte Corporation (Nasdaq:INCY) announces updated data from its ongoing Phase 2 FIGHT-202 trial evaluating pemigatinib (INCB54828), its selective fibroblast growth factor receptor (FGFR) inhibitor, in patients with advanced/metastatic or surgically unresectable cholangiocarcinoma (bile duct cancer) who failed at least one previous treatment. In patients with FGFR2 translocations who were followed for at least eight months, interim study results demonstrated an overall response rate (ORR) of 40 percent, the primary endpoint, and a median progression free survival (PFS) of 9.2 months, a key secondary endpoint. These results are being presented at the European Society for Medical Oncology (ESMO) 2018 Congress in Munich, Germany in a poster presentation on Sunday, October 21 from 12:45 p.m. CEST to 1:45 p.m. CEST (6:45 a.m. ET to 7:45 a.m. ET). (Location: Hall A3 – Poster Area Networking Hub; Abstract #756P) “We are pleased to share updated interim results from our ongoing FIGHT-202 trial
Servier and Taiho Oncology Announce Phase III LONSURF® Study Has Met Primary and Secondary Endpoints Demonstrating Prolonged Overall Survival and Progression-Free Survival in Patients with Refractory Metastatic Gastric Cancer21.10.2018 12:10 | Tiedote
Servier and Taiho Oncology, Inc. (U.S.), a subsidiary of Taiho Pharmaceutical Co., Ltd. (Japan), jointly announced today clinical data from the pivotal Phase III TAS-102 Gastric Study (TAGS) evaluating LONSURF® (trifluridine/tipiracil, TAS-102) versus placebo and best supportive care in patients with heavily pre-treated metastatic gastric cancer who have progressed or are intolerant to previous lines of therapy. The study met its primary endpoint of prolonged overall survival (OS) and secondary endpoint measures of progression-free survival (PFS) consistently supported the OS results, as well as continuing to demonstrate the predictable safety and tolerability profile of trifluridine/tipiracil. Data from TAGS was presented by Dr. Hendrik-Tobias Arkenau, Executive Medical Director of the Sarah Cannon Research Institute UK and an investigator for TAGS, at the ESMO 2018 Congress in Munich, Germany during an oral session (Abstract #LBA25). The study results were simultaneously published in
Phase 3 Data on Filgotinib in Biologic-Experienced Rheumatoid Arthritis to Be Presented at 2018 ACR/ARHP Annual Meeting21.10.2018 01:30 | Tiedote
Gilead Sciences, Inc. (Nasdaq: GILD) and Galapagos NV (Euronext & NASDAQ: GLPG) today announced detailed results from the Phase 3 FINCH 2 clinical trial of filgotinib, an investigational, selective JAK1 inhibitor, in adults with moderately-to-severely active rheumatoid arthritis and prior inadequate response or intolerance to biologic agents. The data, which are being presented as a late-breaking poster at the 2018 American College of Rheumatology/Association of Rheumatology Health Professionals (ACR/ARHP) Annual Meeting in Chicago, suggest filgotinib has a potential role in addressing important unmet needs in the treatment of rheumatoid arthritis. Positive efficacy data from FINCH 2 were previously announced in September 2018. The data show statistically significant improvements in the proportion of patients achieving a range of clinical efficacy endpoints, including the proportion of patients achieving American College of Rheumatology 20 percent (ACR20, primary endpoint), 50 percent
Manchester United and True Religion Launch Denim Range19.10.2018 20:37 | Tiedote
Manchester United (NYSE:MANU) and luxury denim brand True Religion have collaborated to launch a range of premium club branded denim wear. A first for the club, the new global partnership with the iconic American denim brand will see a range of men’s & women’s co-branded styles go on sale beginning 26th October in the club’s Megastore as well as online via United Direct and truereligion.com & eu.truereligion.com. The exclusive collection features jeans, shirts and jackets, including a highly desirable limited edition denim jacket embroidered with the club’s crest. Fans will have the opportunity to win a selection of clothing from the new range by visiting www.manutd.com/truereligion. Manchester United’s Group Managing Director, Richard Arnold, comments: “True Religion is a well-known, established name in fashion, creating unique designs without compromising on quality. The range we have collaborated on includes the same attention to detail and craftsmanship that has made True Religion
Arch Insurance Announces Strategic Leadership Changes19.10.2018 16:10 | Tiedote
Arch Insurance today announced that Matt Shulman will assume the newly created role of CEO, Arch Insurance North America, effective January 1, 2019. In this role, he will lead Arch Insurance’s operations in the United States and Canada. He will report to Nicolas Papadopoulo, Chairman and CEO of Arch Worldwide Insurance Group. Mr. Shulman, who has more than 20 years of experience in the insurance industry, has been with Arch Insurance since 2009 and has served as the President and CEO of Arch Insurance Europe since 2016. “Matt brings significant U.S. and international experience to this role. Under his leadership, together with our senior team, Arch Insurance will continue to enhance our value proposition to our customers through a robust, diversified product portfolio, creative solutions and excellent service,” Mr. Papadopoulo said. Arch Insurance has also created a new organizational structure with three Chief Underwriting Officers (CUO) dedicated to specific lines of business. These
Takeda to Present Results from Phase 3 ALTA-1L Trial Highlighting Intracranial Efficacy of ALUNBRIG® (brigatinib) Versus Crizotinib in First-Line Advanced ALK+ Non-Small Cell Lung Cancer19.10.2018 15:00 | Tiedote
Takeda Pharmaceutical Company Limited (TSE: 4502) today announced that intracranial efficacy data from the Phase 3 ALTA-1L (ALK in Lung Cancer Trial of BrigAtinib in 1 st Line) trial showed improved intracranial progression-free survival (PFS) and intracranial objective response rate (ORR) with ALUNBRIG (brigatinib) compared to crizotinib among anaplastic lymphoma kinase-positive (ALK+) non-small cell lung cancer (NSCLC) patients. Data for these secondary endpoints will be presented in a poster discussion at the European Society for Medical Oncology (ESMO) 2018 Congress on Friday, October 19 at 2:00 p.m. CET in Munich, Germany. These results further support ALUNBRIG as a potential treatment for adults with ALK+ locally advanced or metastatic NSCLC who had not received a prior ALK inhibitor. ALUNBRIG is currently not approved as first-line therapy for advanced ALK+ NSCLC. “ALK+ NSCLC often spreads to the brain, so having options that can clearly demonstrate efficacy both in the brain an
Uutishuoneessa voit lukea tiedotteitamme ja muuta julkaisemaamme materiaalia. Löydät sieltä niin yhteyshenkilöidemme tiedot kuin vapaasti julkaistavissa olevia kuvia ja videoita. Uutishuoneessa voit nähdä myös sosiaalisen median sisältöjä. Kaikki STT Infossa julkaistu materiaali on vapaasti median käytettävissä.Tutustu uutishuoneeseemme